TVARDI THERAPEUTICS, INC. Investment Income, Net
TVARDI THERAPEUTICS, INC. (TVRD) reported Investment Income, Net of $172.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. investment income, net for the quarter ending 2026-06-30 was $172.00K, a 54.38% decline year-over-year.
- TVARDI THERAPEUTICS, INC. investment income, net for the quarter ending 2026-03-31 was $247.00K, a 10.18% decline year-over-year.
- TVARDI THERAPEUTICS, INC. investment income, net for the quarter ending 2025-12-31 was $312.00K, a 136.36% increase year-over-year.
- TVARDI THERAPEUTICS, INC. investment income, net for the quarter ending 2025-09-30 was $411.00K, a 152.15% increase year-over-year.
- TVARDI THERAPEUTICS, INC. investment income, net for fiscal 2025 was $1.38M, a 84.07% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. investment income, net for fiscal 2024 was $747.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $172.00K 10-Q · filed 2026-08-14 | $419.00K 10-Q · filed 2026-08-14 | $731.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.14M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $247.00K 10-Q · filed 2026-05-08 | $559.00K derived: sum of 2 quarters · filed 2026-05-08 | $970.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $723.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.10M derived: sum of 3 quarters · filed 2026-08-14 | $1.38M 10-K · filed 2026-03-31 |
| 2025-09-30 | $411.00K 10-Q · filed 2025-11-13 | $788.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.06M 10-Q · filed 2025-11-13 | $1.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $377.00K 10-Q · filed 2026-08-14 | $652.00K 10-Q · filed 2026-08-14 | $784.00K derived: sum of 3 quarters · filed 2026-08-14 | $947.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $275.00K 10-Q · filed 2026-05-08 | $407.00K derived: sum of 2 quarters · filed 2026-05-08 | $570.00K derived: sum of 3 quarters · filed 2026-05-08 | $776.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $295.00K derived: sum of 2 quarters · filed 2026-03-31 | $501.00K derived: sum of 3 quarters · filed 2026-03-31 | $747.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $163.00K 10-Q · filed 2025-11-13 | $369.00K derived: sum of 2 quarters · filed 2025-11-13 | $615.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $206.00K 10-Q · filed 2025-08-14 | $452.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |